Drugs / SA58
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05667714 | Nov → Dec 2022 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05664919 | Oct → Dec 2022 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-12-15 | Sinovac Biotech Co., Ltd | Results 对多种奥密克戎变异株广谱有效 新冠病毒广谱单克隆抗体为防治带来新希望 sinovac.com ↗
体外中和试验和动物模型研究显示，SA58和SA55无论单独使用或同时使用均具有作为针对新冠病毒的广谱性治疗或预防用药的潜在价值。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-15 | Sinovac Biotech Co., Ltd | 对多种奥密克戎变异株广谱有效 新冠病毒广谱单克隆抗体为防治带来新希望 sinovac.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA58 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664919 ↗ |
| Known as | SA58 Nasal Spray | “Drug: SA58 Nasal Spray” NCT05664919 ↗ |
| Modality | Protein / enzyme biologic | “mainly consists of neutralizing antibody of COVID-19” NCT05667714 ↗ |
| Route | Intranasal | “The medication is self-administered intranasally” NCT05664919 ↗ |